Intraocular concentrations of chemotherapeutic agents after systemic or local administration

被引:67
作者
Mendelsohn, ME
Abramson, DH
Madden, T
Tong, W
Tran, HT
Dunkel, IJ
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA
[2] Univ Texas, Md Anderson Canc Ctr, Clin Pharmacol Resources Facil, Houston, TX USA
[3] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA
关键词
D O I
10.1001/archopht.116.9.1209
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objectives: To investigate the concentrations of carboplatin and etoposide achieved in the aqueous and vitreous humors after intravenous infusion in nonhuman primates, and to investigate whether local administration of carboplatin might result in higher concentrations in the vitreous humor. Methods: Macaca fascicularis primates were treated with 1 of 3 regimens: (1) intravenous carboplatin (18.7 mg/kg), etoposide (5 mg/kg), and vincristine sulfate (0.05 mg/kg), (2) peribulbar carboplatin(10 mg/mL), or (3) episcleral balloon carboplatin(10 mg/mL). Concentrations of chemotherapeutic agents were measured in the plasma and in the aqueous and vitreous humors. Results: No measurable amount of etoposide was detected in the aqueous or vitreous humor after intravenous administration. Mean measured peak vitreous concentration of carboplatin after intravenous administration was 0.31 mu g/mL, which was 1% of the peak plasma value. Mean measured peak vitreous concentrations of carboplatin after peribulbar or episcleral balloon administration were 2.38 mu g/mL and 2.95 mu g/mL, respectively, which represent 7.68- and 9.52-fold increases over the concentration achieved after intravenous administration. No serious toxic effect was observed in any animal. Conclusions: Peribulbar and episcleral balloon administration of carboplatin seemed to be safe and resulted in higher vitreous concentrations than intravenous administration in this model. These results suggest that these alternate routes of delivery should be explored in children with vitreous seeding of retinoblastoma.
引用
收藏
页码:1209 / 1212
页数:4
相关论文
共 18 条
[1]  
ABRAMSON DH, 1981, ARCH OPHTHALMOL-CHIC, V99, P1763
[2]  
ANDRACCHI S, 1996, INVEST OPHTH VIS SCI, V37, P3
[3]  
BALIS FM, 1997, PRINCIPLES PRACTICE, P228
[4]  
CHAN HSL, 1995, INT J PEDIAT HEM ONC, V2, P269
[5]  
DUNKEL IJ, 1996, P AM SOC CLIN ONCOL, V15, pA1439
[6]   MORTALITY FROM 2ND TUMORS AMONG LONG-TERM SURVIVORS OF RETINOBLASTOMA [J].
ENG, C ;
LI, FP ;
ABRAMSON, DH ;
ELLSWORTH, RM ;
WONG, FL ;
GOLDMAN, MB ;
SEDDON, J ;
TARBELL, N ;
BOICE, JD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (14) :1121-1128
[7]   Treatment of intraocular retinoblastoma with carboplatin and etoposide chemotherapy [J].
Greenwald, MJ ;
Strauss, LC .
OPHTHALMOLOGY, 1996, 103 (12) :1989-1997
[8]  
Harbour JW, 1996, INVEST OPHTH VIS SCI, V37, P1892
[9]   Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma [J].
Kingston, JE ;
Hungerford, JL ;
Madreperla, SA ;
Plowman, PN .
ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (11) :1339-1343
[10]  
Lincoff H, 1996, ARCH OPHTHALMOL-CHIC, V114, P634